Literature DB >> 18426845

The cost-effectiveness of syndromic management for male sexually transmitted disease patients with urethral discharge symptoms and genital ulcer disease in Taiwan.

C-H Tsai1, T-C Lee, H-L Chang, L-H Tang, C-C Chiang, K-T Chen.   

Abstract

OBJECTIVE: To assess the cost-effectiveness of syndromic management for the treatment of sexually transmitted diseases (STD) in comparison with the strategies currently used in STD clinics in Taiwan.
METHODS: Between July 2004 and June 2005, all male patients with genitourinary symptoms attending two hospitals were included in this study. Current clinical procedures (presumptive treatment and laboratory tests), aetiological diagnosis and syndromic management were compared in terms of diagnostic accuracy, treatment appropriateness, costs and effectiveness.
RESULTS: 473 patients met the inclusion criteria and were enrolled in the study. 335 patients (71%) had urethral symptoms (discharge, dysuria or painful urination) and 138 (29%) had genital ulcers, sores and skin rashes. For the current approach, the sensitivity, specificity and positive predictive value (PPV) for the detection of chlamydial, gonococcal and combined forms of infection were 100%, 40.0% and 60.4%, respectively. In contrast, the sensitivity, specificity and PPV for the detection of syphilis were 100%, 86.7% and 70.2%, respectively. For syndromic management, the sensitivity, specificity and PPV detection of chlamydial, gonococcal and combined forms of infection were 85.0%, 40.0% and 56.4%, respectively. In contrast, the sensitivity, specificity and PPV for the detection of syphilis were 78.8%, 18.1% and 23.2%, respectively. The average cost of implementing a correct treatment using the current approach was US$54.27 and US$30.74 for urethritis and syphilis, respectively. For the aetiological approach, the average cost of implementing a correct treatment was US$32.83 and US$21.58 for urethritis and syphilis, respectively. For the syndromic approach, the average cost for a correct treatment was US$3.86 and US$14.30 for urethritis and syphilis, respectively.
CONCLUSIONS: In this sample of patients attending STD clinics in Taiwan, syndromic management was found to be a more cost-effective protocol in terms of cost per treated STD patient compared with the current and aetiological protocols for STD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18426845     DOI: 10.1136/sti.2007.028829

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  5 in total

1.  An Update on the Global Epidemiology of Syphilis.

Authors:  Noah Kojima; Jeffrey D Klausner
Journal:  Curr Epidemiol Rep       Date:  2018-02-19

Review 2.  Diagnosing sexually transmitted infections in resource-constrained settings: challenges and ways forward.

Authors:  Teodora Ec Wi; Francis J Ndowa; Cecilia Ferreyra; Cassandra Kelly-Cirino; Melanie M Taylor; Igor Toskin; James Kiarie; Nancy Santesso; Magnus Unemo
Journal:  J Int AIDS Soc       Date:  2019-08       Impact factor: 5.396

3.  The Diagnostic Accuracy of Syndromic Management for Genital Ulcer Disease: A Systematic Review and Meta-Analysis.

Authors:  Andre J W Loh; Ee Lynn Ting; Teodora E Wi; Philippe Mayaud; Eric P F Chow; Nancy Santesso; Jane Falconer; Richard Ofori-Asenso; Jason J Ong
Journal:  Front Med (Lausanne)       Date:  2022-01-03

4.  Assessment of Using the Syndromic Approach in Managing Patients With Sexually Transmitted Diseases Among the National Guard Primary Health Care Physicians, Jeddah City, Saudi Arabia.

Authors:  Hani S Almugti; Ruqaiyah N Al Hakeem; Ahmed M Alghamdi; Sarah A Aldamen; Abdullah A Alfaifi; Salam Algharbi; Mohammed A Al-Shehri; Essa M Atafi; Abdullah Al Rashidi; Norah Alturki; Abdullah S Al Amer; Shahd O AlMarei; Abdulaziz A Al Hunaiti; Asma S Al Shabragi; Asmaa S Al Barakati
Journal:  Cureus       Date:  2022-01-22

5.  Syndromic management and STI control in urban Peru.

Authors:  Jesse L Clark; Andres G Lescano; Kelika A Konda; Segundo R Leon; Franca R Jones; Jeffrey D Klausner; Thomas J Coates; Carlos F Caceres
Journal:  PLoS One       Date:  2009-09-25       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.